Development trend of cell culture
Development trend of cell culture
Cell culture has now become one of the main technologies used in life science. It is a general term for taking some tissues from the biological body and dispersing them into single cells or directly taking single cells from the body and cultivating them in an artificial environment conducive to growth. Cell culture media usually include appropriate cell energy sources and compounds that regulate the cell cycle. A typical medium also needs to be supplemented with amino acids, vitamins, inorganic salts, glucose, and serum to provide growth factors, hormones, and attachment factors.
market size
In 2021, China's culture medium market reached 2.63 billion yuan, with a compound annual growth rate of 44.0% from 2017 to 2021. It is expected that China's cell culture medium market will reach 7.1 billion yuan in 2022, with a compound annual growth rate of 22.0% from 2021 to 2026. Thanks to the continuous growth of the downstream biopharmaceutical / pharmaceutical market, the cell culture medium market has also expanded. China's biopharmaceutical / pharmaceutical development is still in its early stage, and there is still great growth potential in the future.
Future development trend
1. Domestic substitution of cell culture medium market continues to accelerate
The R & D strength of local enterprises has been continuously strengthened, and they are gradually breaking the technological monopoly of imported culture medium manufacturers to achieve the successful development of high-end culture medium for antibody and cell therapy production. With the in-depth implementation of price negotiation and volume purchase, biopharmaceuticals / products are facing certain price pressure, and the reduction of production costs can effectively alleviate the competitive pressure of manufacturers, Domestic culture medium manufacturers will continue to replace the market share of imported manufacturers through flexible pricing strategies.
2. Customized development medium
The cell line corresponding to each biopharmaceutical / product can optimize the yield through the regulation of culture medium, but the development of culture medium usually aims at developing the same culture medium for similar cell lines, which simplifies the type of culture medium product and sacrifices the yield of biopharmaceutical / product. At present, more flexible local manufacturers are adopting the strategy of customized development of culture medium to meet customer needs, improve productivity and reduce costs, which is expected to become a new choice for many heavy drugs in the future.
Shenyang GREAT ELITES Intelligent Equipment Co., Ltd. is committed to providing customers with professional intelligent biopharmaceutical production overall solutions. Involving the biopharmaceutical industry, it is a digital and intelligent production workshop. Strict project control and high-quality after-sales service solve the pain points in the production process for customers, and greatly improve the production efficiency and process safety.
The company's team has more than 10 years of experience in the production and manufacturing of biopharmaceutical equipment, is familiar with the biopharmaceutical production process, can help customers plan the production process, customize and upgrade solutions according to the actual production situation of customers, and use continuously innovative technologies to improve product quality, improve production efficiency and save production costs for customers.
The CFAM series cell factory automation equipment developed by the company has completed the task of processing the cell culture process, created the first application of such equipment in the production of biotechnology vaccines in China, and provided strong support for the mass production of covid-19 vaccine, rabies vaccine, hepatitis A vaccine and other vaccines. The adoption of CFAM series cell factory automation equipment of our company has brought the highest clean level GMP a, higher production efficiency, shortened the time to market, and achieved the purpose of cost reduction, efficiency increase and compliant production.